Entrada Therapeutics, Inc.
TRDA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TRDA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TRDA
Entrada Therapeutics, Inc. (TRDA) is a biopharmaceutical company developing intracellular biologics for Duchenne muscular dystrophy and other diseases, with a cash runway into the third quarter of 2027 and a net loss of $42.8M in the latest quarter.
Key risk: Financing risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials for Entrada Therapeutics, Inc..
Entrada Therapeutics, Inc. (TRDA) is a biopharmaceutical company developing intracellular biologics for Duchenne muscular dystrophy and other diseases, with a cash runway into the third quarter of 2027 and a net loss of $42.8M in the latest quarter.
- Cash and equivalents of $102.6M as of 2026-06-30 [sec].
- Total revenue of $0.9M and net loss of $42.8M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $306.1M as of 2026-06-30 [sec].
- Accumulated deficit of $233.9M as of September 30, 2025 [sec_mda · as of 2025-11-06].
- Cash runway expected to fund operations into the third quarter of 2027 based on plans as of December 31, 2025 [sec_mda · as of 2026-02-26].
What works
- Cash and equivalents of $102.6M as of 2026-06-30 provide a near-term funding buffer for ongoing clinical programs [sec].
- Shareholders' equity of $306.1M as of 2026-06-30 indicates a solid balance sheet relative to current operating losses [sec].
- The company has a clear clinical development timeline with multiple cohorts and studies planned for 2026, including ELEVATE-44-102 and Phase 1/2 MAD studies for ENTR-601-45 and ENTR-601-50 [sec · filed 2026-01-08].
What to weigh
- The company has an accumulated deficit of $233.9M as of September 30, 2025, reflecting a history of operating losses [sec_mda · as of 2025-11-06].
- Net loss of $42.8M in the latest quarter (2026-06-30) indicates ongoing cash burn that will require future financing [sec].
- The company expects significant expenses and operating losses for the foreseeable future and may need to delay or reduce programs if additional funding is not secured [sec_mda · as of 2026-02-26].
- No revenue from product sales is expected unless and until regulatory approval is obtained, which is uncertain [sec_mda · as of 2025-11-06].
From the filings
Quoted directly from source documents.
Cash runway into third quarter of 2027
“we believe that our cash, cash equivalents and marketable securities as of December 31, 2025 will be sufficient to fund our operations into the third quarter of 2027.”
SEC MD&A · February 26, 2026
Accumulated deficit of $233.9M
“we had an accumulated deficit of $233.9 million.”
SEC MD&A · November 6, 2025
Expectation of significant operating losses
“significant expenses and operating losses for the foreseeable future as we advance the preclinical and, if successful, the clinical development of our programs.”
SEC MD&A · February 26, 2026
Clinical development timeline for 2026
“expectations regarding initiation of the planned ELEVATE-44-102 study in the U.S. in the first half of 2026, expectations regarding the Company's Phase 1/2 MAD clinical study of ENTR-601-45, including the timing of data from Cohort 1 in mid-2026”
SEC filings · January 8, 2026
Risks & what to watch (3)›
Key risks
- Financing risk — If additional funding is not secured, the company may be forced to delay or reduce programs [sec_mda · as of 2026-02-26].
- Clinical development risk — No product revenue until regulatory approval, which is uncertain and may not occur [sec_mda · as of 2025-11-06].
- Operating loss trajectory — Net loss of $42.8M in the latest quarter and accumulated deficit of $233.9M indicate ongoing cash burn [sec].
What to watch
- Initiation of the ELEVATE-44-102 study in the U.S. in the first half of 2026 [sec · filed 2026-01-08].
- Data from Cohort 1 of the Phase 1/2 MAD study of ENTR-601-45 expected in mid-2026 [sec · filed 2026-01-08].
- Regulatory filings in the EU for the Phase 1/2 MAD study of ENTR-601-50 in the second half of 2026 [sec · filed 2026-01-08].
- Global regulatory filings for the planned clinical study of ENTR-601-51 in 2026 [sec · filed 2026-01-08].
Sources: SEC filings · SEC MD&A · Generated August 17, 2026 · How we verify sources →
Run Entrada Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Entrada Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
13.1 months
D/E 0.28 · 0% dilution
Lead: Phase 1/Phase 2
6 candidates
No upcoming catalysts tracked
1 buy · 17 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
116
Total value held
$239.7M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 5,072,730 | $64.0M |
| vanguard capital management llc | 2,512,026 | $31.7M |
| blackrock, inc. | 2,358,793 | $29.8M |
| wellington management group llp | 1,034,782 | $13.1M |
| geode capital management, llc | 667,347 | $8.4M |
| state street corp | 533,798 | $6.7M |
| millennium management llc | 519,356 | $6.6M |
| woodline partners lp | 431,954 | $5.5M |
| jones hill capital lp | 374,010 | $4.7M |
| jacobs levy equity management, inc | 333,914 | $4.2M |
Showing top 10 of 116 institutional holders of Entrada Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 4.3%
- Days to cover
- 3.9
- Shares short
- 894,152
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TRDA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Entrada Therapeutics, Inc.?
Entrada Therapeutics, Inc. (TRDA) is a biopharmaceutical company developing intracellular biologics for Duchenne muscular dystrophy and other diseases, with a cash runway into the third quarter of 2027 and a net loss of $42.8M in the latest quarter.
What is Entrada Therapeutics, Inc.'s lead drug candidate?
Entrada Therapeutics, Inc.'s most advanced tracked candidate is entr-601-44 (Phase 1/Phase 2) for Duchenne Muscular Dystrophy (DMD).
Who is the CEO of Entrada Therapeutics, Inc.?
Mr. Dipal Doshi is the chief executive officer of Entrada Therapeutics, Inc. (TRDA).
Where is Entrada Therapeutics, Inc. headquartered?
Entrada Therapeutics, Inc. (TRDA) is headquartered in Boston, MA, United States.
What therapeutic areas does Entrada Therapeutics, Inc. focus on?
Entrada Therapeutics, Inc. develops therapies across Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.